<DOC>
	<DOCNO>NCT02064699</DOCNO>
	<brief_summary>Cytomegalovirus ( CMV ) infection observe 30 % organ recipient high morbidity . Moreover , prophylaxis , 75 % R + D-transplanted , 55 % , R + D + D-25 % R + develop CMV . The number available antiviral drug reduce noticeable side effect ( neutropenia , renal toxicity ) lead premature discontinuation therapy use reduce dos promote non-response treatment emergence resistance . In case neutropenia , increase risk secondary rejection due reduction immunosuppressive treatment render necessary haematological reach . Rational use molecule necessary essential today optimal duration prophylaxis primary issue prophylaxis recurrence case CMV infection report .</brief_summary>
	<brief_title>Assessing Risk CMV Infection Renal Transplant About R + Cellular Immunity Analyzed QuantiFERON ®-CMV Test .</brief_title>
	<detailed_description>QuantiFERON-CMV ® fast standardize test evaluates CMV specific cellular immunity measure amount secrete Interferon gamma ( IFN gamma ) plasma ELISA . It use epitope protein include CMV glycoprotein B ( gB ) , protein IE-1 protein pp65 protein pp50 , specific ( human leukocyte antigen ) HLA class I. Pretreatment sample simple plasma store , frozen , delay dose interferon .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Renal transplant recipient Immunized Cytomegalovirus Not willing participate , health insurance clinical evidence active viral infection renal transplant recipient whose treatment include induction antilymphocyte antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Renal transplant</keyword>
	<keyword>CMV</keyword>
	<keyword>Test QuantiFERON-CMV</keyword>
</DOC>